1 |
ROEHLEN N, CROUCHET E, BAUMERT T F. Liver fibrosis: Mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9(4): 875. doi:10.3390/cells9040875
doi: 10.3390/cells9040875
|
2 |
AIROLA C, PALLOZZI M, CERRITO L, et al. Microvascular thrombosis and liver fibrosis progression: mechanisms and clinical applications[J]. Cells, 2023, 12(13): 1712. doi:10.3390/cells12131712
doi: 10.3390/cells12131712
|
3 |
MAOUIA A, REBETZ J, KAPUR R, et al. The immune nature of platelets revisited[J]. Transfus Med Rev, 2020, 34(4): 209-220. doi:10.1016/j.tmrv.2020.09.005
doi: 10.1016/j.tmrv.2020.09.005
|
4 |
YIN H, SHI A, WU J. Platelet-activating factor promotes the development of non-alcoholic fatty liver disease[J]. Diabetes Metab Syndr Obes, 2022, 15: 2003-2030. doi:10.2147/dmso.s367483
doi: 10.2147/dmso.s367483
|
5 |
POISSON J, LEMOINNE S, BOULANGER C, et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases[J]. J Hepatol, 2017, 66(1): 212-227. doi:10.1016/j.jhep.2016.07.009
doi: 10.1016/j.jhep.2016.07.009
|
6 |
DIDAMOONY M A, ATWA A M, AHMED L A. A novel mechanistic approach for the anti-fibrotic potential of rupatadine in rat liver via amendment of PAF/NF-ĸB p65/TGF-β1 and hedgehog/HIF-1α/VEGF trajectories[J]. Inflammopharmacology, 2023, 31(2): 845-858. doi:10.1007/s10787-023-01147-7
doi: 10.1007/s10787-023-01147-7
|
7 |
MEYER J, BALAPHAS A, FONTANA P, et al. Platelet interactions with liver sinusoidal endothelial cells and hepatic stellate cells lead to hepatocyte proliferation[J]. Cells, 2020, 9(5): 1243. doi:10.3390/cells9051243
doi: 10.3390/cells9051243
|
8 |
FENG Y, DONG H, SUN B, et al. METTL3/METTL14 transactivation and m(6)a-dependent TGF-β1 translation in activated kupffer cells[J]. Cell Mol Gastroenterol Hepatol, 2021, 12(3): 839-856. doi:10.1016/j.jcmgh.2021.05.007
doi: 10.1016/j.jcmgh.2021.05.007
|
9 |
SINGH S, ANSHITA D, RAVICHANDIRAN V. MCP-1: Function, regulation, and involvement in disease[J]. Int Immunopharmacol, 2021, 101(Pt B): 107598. doi:10.1016/j.intimp.2021.107598
doi: 10.1016/j.intimp.2021.107598
|
10 |
HAMMERICH L, TACKE F. Hepatic inflammatory responses in liver fibrosis[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(10): 633-646. doi:10.1038/s41575-023-00807-x
doi: 10.1038/s41575-023-00807-x
|
11 |
SUN Y, LIU B, XIE J, et al. Aspirin attenuates liver fibrosis by suppressing TGF-β1/Smad signaling[J]. Mol Med Rep, 2022, 25(5): 181. doi:10.3892/mmr.2022.12697
doi: 10.3892/mmr.2022.12697
|
12 |
WANG T, FU X, JIN T, et al. Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma[J]. EBioMedicine, 2019, 45: 168-180. doi:10.1016/j.ebiom.2019.06.048
doi: 10.1016/j.ebiom.2019.06.048
|
13 |
JIANG Z G, FELDBRüGGE L, TAPPER E B, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States[J]. Aliment Pharmacol Ther, 2016, 43(6): 734-743. doi:10.1111/apt.13515
doi: 10.1111/apt.13515
|
14 |
SEVERO M D. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2020, 18(2): 523. doi:10.1016/j.cgh.2019.05.034
doi: 10.1016/j.cgh.2019.05.034
|
15 |
DU Z Q, ZHAO J Z, DONG J, et al. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study[J]. World J Gastroenterol, 2019, 25(28): 3798-3807. doi:10.3748/wjg.v25.i28.3798
doi: 10.3748/wjg.v25.i28.3798
|
16 |
LEE T Y, HSU Y C, TSENG H C, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B[J]. JAMA Intern Med, 2019, 179(5): 633-640. doi:10.1001/jamainternmed.2018.8342
doi: 10.1001/jamainternmed.2018.8342
|
17 |
HILSCHER M B, SHAH V H. Small but mighty: Platelets in NASH and other chronic liver diseases[J]. Hepatology, 2020, 71(4): 1501-1504. doi:10.1002/hep.31101
doi: 10.1002/hep.31101
|
18 |
CHEN C, CHEN J, WANG Y, et al. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling[J]. Phytomedicine, 2023, 110: 154626. doi:10.1016/j.phymed.2022.154626
doi: 10.1016/j.phymed.2022.154626
|
19 |
POUJOL-ROBERT A, BOËLLE P Y, CONTI F, et al. Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation [J]. Clin Res Hepatol Gastroenterol, 2014, 38(5): 570-576. doi:10.1016/j.clinre.2014.07.004
doi: 10.1016/j.clinre.2014.07.004
|
20 |
PAVLOVIĆ N, KOPSIDA M, GERWINS P, et al. Inhibiting P2Y12 in Macrophages induces endoplasmic reticulum stress and promotes an anti-tumoral phenotype[J]. Int J Mol Sci, 2020, 21(21): 8177. doi:10.3390/ijms21218177
doi: 10.3390/ijms21218177
|
21 |
CZAJKA P, PRZYBYŁKOWSKI A, NOWAK A, et al. Antiplatelet drugs and liver fibrosis[J]. Platelets, 2022, 33(2): 219-228. doi:10.1080/09537104.2021.1883574
doi: 10.1080/09537104.2021.1883574
|
22 |
SCHWARZKOPF K, BOJUNGA J, RüSCHENBAUM S, et al. Use of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease[J]. Hepatol Commun, 2018, 2(12): 1601-1609. doi:10.1002/hep4.1254
doi: 10.1002/hep4.1254
|
23 |
HAN K, ZHANG Y, YANG Z. Cilostazol protects rats against alcohol-induced hepatic fibrosis via suppression of TGF-β1/CTGF activation and the cAMP/Epac1 pathway[J]. Exp Ther Med, 2019, 17(3): 2381-2388.
|
24 |
MAHMOUD N I, MESSIHA B A S, SALEHC I G, et al. Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats[J]. Life Sci, 2019, 231: 116522. doi:10.1016/j.lfs.2019.05.078
doi: 10.1016/j.lfs.2019.05.078
|
25 |
KRILL T, BROWN G, WEIDEMAN R A, et al. Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding, but no increased mortality[J]. Aliment Pharmacol Ther, 2017, 46(2): 183-192. doi:10.1111/apt.14121
doi: 10.1111/apt.14121
|
26 |
SASSO R, ROCKEY D C. Anticoagulation therapy in patients with liver cirrhosis is associated with an increased risk of variceal hemorrhage[J]. Am J Med, 2019, 132(6): 758-766. doi:10.1016/j.amjmed.2019.01.006
doi: 10.1016/j.amjmed.2019.01.006
|
27 |
IANNACONE M, GUIDOTTI L G. Immunobiology and pathogenesis of hepatitis B virus infection[J]. Nat Rev Immunol, 2022, 22(1): 19-32. doi:10.1038/s41577-021-00549-4
doi: 10.1038/s41577-021-00549-4
|
28 |
JANG H, LEE Y B, MOON H, et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis[J]. Hepatology, 2022, 76(2): 492-501. doi:10.1002/hep.32380
doi: 10.1002/hep.32380
|
29 |
LEE C H, LEE Y B, MOON H, et al. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2023, 58(7): 704-714. doi:10.1111/apt.17643
doi: 10.1111/apt.17643
|
30 |
TAN J L, SIDHU-BRAR S, WOODMAN R, et al. Regular aspirin use is associated with a reduced risk of hepatocellular carcinoma (HCC) in chronic liver Disease: a systematic review and meta-analysis[J]. J Gastrointest Cancer, 2023, 54(2): 325-331. doi:10.1007/s12029-022-00842-y
doi: 10.1007/s12029-022-00842-y
|
31 |
SIMON T G, DUBERG A S, ALEMAN S, et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality[J]. N Engl J Med, 2020, 382(11): 1018-1028. doi:10.1056/nejmoa1912035
doi: 10.1056/nejmoa1912035
|